Early‐morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time‐to‐ ON Questionnaire

2019 ◽  
Vol 26 (5) ◽  
pp. 821-826 ◽  
Author(s):  
F. Stocchi ◽  
C. Coletti ◽  
S. Bonassi ◽  
F. G. Radicati ◽  
L. Vacca
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Morning ◽  
Levodopa Dose ◽  
Clinical Appointment

Early morning akinesia in Parkinson's disease: Effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa

Neurology ◽  
1996 ◽  
Vol 46 (4) ◽  
pp. 1059-1062 ◽  
Author(s):  
R. Pahwa ◽  
K. Lyons ◽  
D. McGuire ◽  
R. Dubinsky ◽  
J. P. Hubble ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Sustained Release ◽  
Early Morning ◽  
Disease Effect

scholarly journals Predicting Parkinson’s Disease Medication Regimen Using Sensor Technology

2021 ◽  
Author(s):  
Jeremy Watts ◽  
Anahita Khojandi ◽  
Rama Vasudevan ◽  
Fatta B. Nahab ◽  
Ritesh Ramdhani
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Random Forest ◽  
Classification Model ◽  
Sensor Data ◽  
Sensor Technology ◽  
Medication Regimen ◽  
Levodopa Dose ◽  
Subjective Data ◽  
Random Forest Classification

Abstract Parkinson’s disease (PD) medication treatment planning is generally based on subjective data through in-office, physicianpatient interactions. The Personal KinetiGraphTM (PKG) has shown promise in enabling objective, continuous remote health monitoring for Parkinson’s patients. In this proof-of-concept study, we propose to use objective sensor data from the PKG and apply machine learning to subtype patients based on levodopa regimens and response. We apply k-means clustering to a dataset of with-in-subject Parkinson’s medication changes—clinically assessed by the PKG and Hoehn & Yahr (H&Y) staging. A random forest classification model was then used to predict patients’ cluster allocation based on their respective PKG data and demographic information. Clinically relevant clusters were developed based on longitudinal dopaminergic regimens—partitioned by levodopa dose, administration frequency, and total levodopa equivalent daily dose—with the PKG increasing cluster granularity compared to the H&Y staging. A random forest classifier was able to accurately classify subjects of the two most demographically similar clusters with an accuracy of 87:9 ±1:3

scholarly journals The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

2003 ◽  
Vol 28 (10) ◽  
pp. 1866-1870 ◽  
Author(s):  
Birgit Högl ◽  
Andreas Rothdach ◽  
Thomas C Wetter ◽  
Claudia Trenkwalder
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Function ◽  
Early Morning ◽  
Periodic Leg Movements ◽  
Leg Movements

CONCURRENCE OF FRAILTY AND PARKINSON’S DISEASE

2012 ◽  
pp. 1-5
Author(s):  
K.P. ROLAND ◽  
K.M.D. CORNETT ◽  
O. THEOU ◽  
J.M. JAKOBI ◽  
G.R. JONES
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cardiovascular Health ◽  
Community Dwelling ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
Physical Frailty ◽  
Levodopa Dose ◽  
Frailty Phenotype ◽  
Age Related

Background: Females with Parkinson’s disease (PD) are at greater risk of frailty than males. Little is known about how age and disease-related characteristics influence frailty in females with PD because frailty studies often exclude persons with underlying neurological pathologies. Objective: To determine age and diseaserelated characteristics that best explain physical frailty in community-dwelling females with and without PD. Design & Measurement: Correlation coefficients described relationships between PD-related characteristics and physical frailty phenotype criteria (Cardiovascular Health Study). Regression analysis identified associations between disease-related characteristics and frailty in non-PD and PD females. Setting: Community-dwelling. Participants: Females with mild to moderate PD (n = 17, mean age = 66 ± 8.5 years) and non-PD (n = 18, mean age = 72 ± 13.2 years) participated. Results: Daily carbidopa-levodopa dose best explained frailty in PD females (β = 0.5), whereas in non-PD females, age (β = 0.7) and comorbidity (β = 0.5) were most associated with frailty. Conclusions: Dopaminergic medication explained frailty in PD and not measures of disease progression (i.e. severity, duration). In females without PD age-related accumulation of comorbidities resulted in greater risk of frailty. This indicates dopaminergic management of PD symptoms may better reflect frailty in females with PD than disease severity or duration. These data suggest the influence of underlying frailty should be considered when managing neurological conditions. Understanding how frailty concurrently exists with PD and how these conditions progress within the aging female will facilitate future care management.

scholarly journals Physical Activity across Frailty Phenotypes in Females with Parkinson’s Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Kaitlyn P. Roland ◽  
Kayla M. D. Cornett ◽  
Olga Theou ◽  
Jennifer M. Jakobi ◽  
Gareth R. Jones
Keyword(s):  
Physical Activity ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Self Report ◽  
Physical Activity Intensity ◽  
Levodopa Dose ◽  
Frailty Phenotype ◽  
Activity Intensity ◽  
Global Positioning ◽  
Reduced Physical Activity

Females with Parkinson’s disease (PD) are vulnerable to frailty. PD eventually leads to decreased physical activity, an indicator of frailty. We speculate PD results in frailty through reduced physical activity.Objective. Determine the contribution of physical activity on frailty in PD (n=15, 65 ± 9 years) and non-PD (n=15, 73 ± 14 years) females.Methods. Frailty phenotype (nonfrail/prefrail/frail) was categorized and 8 hours of physical activity was measured using accelerometer, global positioning system, and self-report. Two-way ANCOVA (age as covariate) was used to compare physical activity between disease and frailty phenotypes. Spearman correlation assessed relationships, and linear regression determined associations with frailty.Results. Nonfrail recorded more physical activity (intensity, counts, self-report) compared with frail. Self-reported physical activity was greater in PD than non-PD. In non-PD, step counts, light physical activity time, sedentary time, and self-reported physical activity were related to frailty (R=0.91). In PD, only carbidopa-levodopa dose was related to frailty (r=0.61).Conclusion. Physical activity influences frailty in females without PD. In PD females, disease management may be a better indicator of frailty than physical activity. Further investigation into how PD associated factors contribute to frailty is warranted.

scholarly journals Az orális levodopakezelés jellegzetességei előrehaladott Parkinson-kórban a marosvásárhelyi neurológiai klinikák tapasztalatában

2019 ◽  
Vol 160 (17) ◽  
pp. 662-669 ◽  
Author(s):  
József Attila Szász ◽  
Szabolcs Szatmári ◽  
Viorelia Constantin ◽  
István Mihály ◽  
Attila Rácz ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multidisciplinary Teams ◽  
Motor Complications ◽  
Levodopa Dose ◽  
Advanced Parkinson’S Disease ◽  
Upper Limits ◽  
Severe Motor ◽  
Administration Rate

Abstract: Introduction: The motor and non-motor complications of Parkinson’s disease impair the patients’ quality of life and limit therapeutical options. There are no clear criteria for ‘advanced’ Parkinson’s disease or for the optimal moment for invasive therapies. There is little evidence regarding the upper limits of levodopa doses, and how these may be influenced by the availability of device-aided therapies. Aim: To analyze substitution therapy in patients with advanced Parkinson’s disease. Method: In our retrospective study, we analyzed the data from all patients with advanced Parkinson’s disease hospitalized between 1st June 2011 and 31st May 2017, receiving combined levodopa treatment at least 4×/day, reporting a minimum of 2 hours off periods, with or without dyskinesia. We analyzed levodopa therapy for patients who were recommended either device-aided or conservative therapy. Results: Out of 311 patients with advanced Parkinson’s disease, for 125 we proposed device-aided therapies whereas in 42 patients we increased the levodopa dose. The average levodopa doses and the administration rate were higher for the 107 patients tested for levodopa-carbidopa intestinal gel. Disease duration, mean levodopa doses and frequency of dosing were all higher in patients proposed for device-aided therapies versus patients with continued conservative treatment. Conclusion: Our patients were on lower levodopa doses (compared to literature), but the combinations were used more often. Device-aided therapies should be considered in patients with severe motor complications who receive at least 750–1000 mg levodopa daily, divided minimum 5×/day. These patients need to be tested in specialized centers by multidisciplinary teams in order to make the best decision for further action. Orv Hetil. 2019; 160(17): 662–669.

Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon

2003 ◽  
Vol 18 (5) ◽  
pp. 573-578 ◽  
Author(s):  
Tomoyuki Uchiyama ◽  
Ryuji Sakakibara ◽  
Takamichi Hattori ◽  
Tomonori Yamanishi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Effect ◽  
Short Term ◽  
Levodopa Dose ◽  
Short Term Effect ◽  
Wearing Off

The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease

2011 ◽  
Vol 17 (1) ◽  
pp. 27-29 ◽  
Author(s):  
Richard W. Walker ◽  
Anna R. Howells ◽  
William K. Gray
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Body Weight ◽  
Levodopa Dose

2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY

2012 ◽  
Vol 18 ◽  
pp. S110 ◽  
Author(s):  
A. Rizos ◽  
T. Klemencic Kozul ◽  
A. Martin ◽  
I. Koch ◽  
S. Tluk ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
International Study ◽  
Early Morning ◽  
Motor Patterns

Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease

2016 ◽  
Vol 17 (5) ◽  
pp. 481-488 ◽  
Author(s):  
Vivian Altmann ◽  
Artur F Schumacher-Schuh ◽  
Mariana Rieck ◽  
Sidia M Callegari-Jacques ◽  
Carlos RM Rieder ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Levodopa Dose
Sign in / Sign up

Export Citation Format

Share Document